Last reviewed · How we verify

IBI112 — Competitive Intelligence Brief

IBI112 (IBI112) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor. Area: Oncology.

phase 3 PD-1 inhibitor PD-1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

IBI112 (IBI112) — Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.. IBI112 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IBI112 TARGET IBI112 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. phase 3 PD-1 inhibitor PD-1
Penpulimab kcqx PENPULIMAB Akeso Biopharma marketed Pd-1 2025-01-01
Tevimbra TISLELIZUMAB Beigene marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2025-01-01
Loqtorzi TORIPALIMAB Coherus Biosciences Inc marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2024-01-01
Unloxcyt COSIBELIMAB Checkpoint Therapeutics Inc marketed Programmed Death Ligand-1 Blocker [EPC] Pd-1 2024-01-01
Jemperli DOSTARLIMAB GSK marketed Programmed Death Receptor-1 Blocking Antibody [EPC] PD-1 2021-01-01
Libtayo CEMIPLIMAB Regeneron Pharmaceuticals marketed PD-1 2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor class)

  1. Sun Yat-sen University · 11 drugs in this class
  2. Bristol-Myers Squibb · 9 drugs in this class
  3. Addpharma Inc. · 7 drugs in this class
  4. Merck Sharp & Dohme LLC · 5 drugs in this class
  5. Shanghai Henlius Biotech · 5 drugs in this class
  6. Innovent Biologics (Suzhou) Co. Ltd. · 5 drugs in this class
  7. Pfizer · 4 drugs in this class
  8. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 4 drugs in this class
  9. Amgen · 3 drugs in this class
  10. Daewoong Pharmaceutical Co. LTD. · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IBI112 — Competitive Intelligence Brief. https://druglandscape.com/ci/ibi112. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: